|
|
|
| home | genetic news | bioinformatics | biotechnology | literature | journals | ethics | positions | events | sitemap |
New Possibility For Polycystic Kidney Disease Treatment
|
In the April issue of Nature Medicine, Vicente Torres and colleagues report a new treatment for polycystic kidney disease (PKD), the fourth leading cause of kidney failure in the US.
PKD is a genetic disorder in which kidneys become overgrown with fluid-filled cysts. The authors tested the drug OPC31260, which blocks an important receptor in kidney cells, in a mouse model of autosomal dominant PKD, the most common form of the disease. The drug blocked disease development in the mice, reducing the number of kidney cysts and preventing the kidneys from becoming enlarged. The authors say OPC31260 and similar drugs should be safe in clinical studies because they specifically target the kidneys. Other drugs targeting the same receptor are currently in clinical trials for diseases such as congestive heart failure and cirrhosis. Author contact: Vicente E. Torres Also available online. (C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser. Use the links below to share this article on the social bookmarking site of your choice. Read more about social bookmarking at Wikipedia - Social Bookmarking |
BioGPS: a centralized online resource for gene annotation Brain Adaptations to Sensory Loss Sequencing Small Chips A Stroke Against Stroke Inhibition Present in Absences Assessing Natural Memory Variant Associated with Alcoholic Liver Disease Parkinson's Gene Mutated in Cancer Mismatch Associated with Graft-Versus-Host-Disease High Levels of HLA-C Associated with Slower HIV/AIDS Progression Feeding Back on Tumour Initiation more news ... |
Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S. Zollmann.
7.0 © 1995-2010 HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint.